Mylan CEO: Neulasta biosimilar will offer “significant savings” for patients

It’s been nearly two years since the pharmaceutical giant took tremendous heat for the rising cost of EpiPens

Categories: Health

Leave a Reply

Your email address will not be published. Required fields are marked *